DZ2845A1 - Calcium (3S) tétrahydro-3-furanyle(1S,2R)-3-ÄÄ(4-aminophényle)sulfonyleÜ(sobutyle)aminoÜ-1-benzyle-2(phosphonooxy)propylcarbamate. - Google Patents

Calcium (3S) tétrahydro-3-furanyle(1S,2R)-3-ÄÄ(4-aminophényle)sulfonyleÜ(sobutyle)aminoÜ-1-benzyle-2(phosphonooxy)propylcarbamate.

Info

Publication number
DZ2845A1
DZ2845A1 DZ990145A DZ990145A DZ2845A1 DZ 2845 A1 DZ2845 A1 DZ 2845A1 DZ 990145 A DZ990145 A DZ 990145A DZ 990145 A DZ990145 A DZ 990145A DZ 2845 A1 DZ2845 A1 DZ 2845A1
Authority
DZ
Algeria
Prior art keywords
sulfonylü
aminoü
sobutyl
propylcarbamate
phosphonooxy
Prior art date
Application number
DZ990145A
Other languages
English (en)
Inventor
Lan Cordon Armitage
Andrew David Sealle
Hardev Singh
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DZ2845A1 publication Critical patent/DZ2845A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DZ990145A 1998-07-18 1999-07-14 Calcium (3S) tétrahydro-3-furanyle(1S,2R)-3-ÄÄ(4-aminophényle)sulfonyleÜ(sobutyle)aminoÜ-1-benzyle-2(phosphonooxy)propylcarbamate. DZ2845A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
DZ2845A1 true DZ2845A1 (fr) 2003-12-01

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ990145A DZ2845A1 (fr) 1998-07-18 1999-07-14 Calcium (3S) tétrahydro-3-furanyle(1S,2R)-3-ÄÄ(4-aminophényle)sulfonyleÜ(sobutyle)aminoÜ-1-benzyle-2(phosphonooxy)propylcarbamate.

Country Status (47)

Country Link
US (3) US6514953B1 (fr)
EP (2) EP1240903A3 (fr)
JP (1) JP3437553B2 (fr)
KR (1) KR100694721B1 (fr)
CN (1) CN1188422C (fr)
AP (1) AP2001002039A0 (fr)
AR (1) AR019388A1 (fr)
AT (1) ATE229964T1 (fr)
AU (1) AU766056B2 (fr)
BG (1) BG105253A (fr)
BR (1) BRPI9912156B8 (fr)
CA (1) CA2337857C (fr)
CO (1) CO5090836A1 (fr)
CZ (1) CZ300447B6 (fr)
DE (1) DE69904600T2 (fr)
DK (1) DK1098898T3 (fr)
DZ (1) DZ2845A1 (fr)
EA (1) EA003191B1 (fr)
EE (1) EE200100038A (fr)
ES (1) ES2189450T3 (fr)
GB (1) GB9815567D0 (fr)
GC (1) GC0000105A (fr)
GE (1) GEP20033030B (fr)
GT (1) GT199900111A (fr)
HR (1) HRP20010046A2 (fr)
HU (1) HU229700B1 (fr)
ID (1) ID28070A (fr)
IL (1) IL140824A (fr)
IS (1) IS5808A (fr)
JO (1) JO2114B1 (fr)
MA (1) MA26660A1 (fr)
MY (1) MY122323A (fr)
NO (1) NO329676B1 (fr)
NZ (1) NZ509291A (fr)
OA (1) OA11706A (fr)
PA (1) PA8477801A1 (fr)
PE (1) PE20000869A1 (fr)
PL (1) PL195736B1 (fr)
PT (1) PT1098898E (fr)
SK (1) SK285311B6 (fr)
SV (1) SV1999000096A (fr)
TN (1) TNSN99145A1 (fr)
TR (1) TR200100111T2 (fr)
TW (1) TWI245770B (fr)
WO (1) WO2000004033A1 (fr)
YU (1) YU3401A (fr)
ZA (1) ZA200100417B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
PL204924B1 (pl) * 1999-10-06 2010-02-26 Tibotec Pharm Ltd Heksahydrofuro [2,3-b] furanylo-3-N-{3(1,3-benzodioksolilo-5-sulfonylo) (izobutylo) amino] -1-benzylo-2-hydroksypropylo} karbaminian oraz jego zastosowanie
HU230030B1 (hu) 1999-10-08 2015-05-28 Debiopharm International Sa Fab I inhibitorok
EP1560584B1 (fr) * 2001-04-06 2009-01-14 Affinium Pharmaceuticals, Inc. Inhibiteurs de fab i
WO2003091264A2 (fr) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Inhibiteurs non nucleosidiques de la transcriptase inverse
EP1575951B1 (fr) * 2002-12-06 2014-06-25 Debiopharm International SA Composes heterocycliques, procedes de production de ceux-ci et utilisation de ceux-ci dans un traitement
WO2004082586A2 (fr) 2003-03-17 2004-09-30 Affinium Pharmaceuticals, Inc. Compositions comportant plusieurs agents antibiotiques, et leurs procedes de mise en oeuvre
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20080234288A1 (en) * 2003-09-30 2008-09-25 Kenneth Alan Simmen Hcv Inhibiting Sulfonamides
WO2005044279A1 (fr) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Conjugues phosphonate / inhibiteur de purine nucleoside phosphorylase
WO2005044308A1 (fr) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Analogues phosphonates d'antimetabolites
WO2005042773A1 (fr) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Procedes et compositions permettant d'identifier des composes therapeutiques
BRPI0417988A (pt) 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
DK1828167T3 (da) * 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
SI2153870T1 (sl) 2004-11-26 2014-05-30 Ucl Business Plc Sestavki, ki obsegajo ornitin in fenilacetat ali fenilbutirat, za zdravljenje hepatitične encefalopatije
KR20080075027A (ko) * 2005-12-05 2008-08-13 아피늄 파마슈티컬스, 인크. Fabi 억제제 및 항박테리아제로서의헤테로시클릴아크릴아미드 화합물
JP5468899B2 (ja) 2006-07-20 2014-04-09 アフィニウム ファーマシューティカルズ, インク. Fabiインヒビターとしてのアクリルアミド誘導体
EP2125802A4 (fr) 2007-02-16 2014-08-20 Debiopharm Int Sa Sels, promédicaments et polymorphes d'inhibiteurs de fab 1
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
WO2010134045A1 (fr) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Fosamprenavir calcique amorphe
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
US20120208787A1 (en) * 2009-06-30 2012-08-16 Ranbaxy Laboratories Limited Crystalline form of fosamprenavir calcium
US9085592B2 (en) 2009-09-16 2015-07-21 Ranbaxy Laboratories Limited Process for the preparation of fosamprenavir calcium
US20110165202A1 (en) * 2010-01-07 2011-07-07 Pliva Hrvatska D.O.O. Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (fr) 2010-03-19 2011-09-22 Lupin Limited Sels d'ammonium, de calcium et de tris de fosamprénavir
US20130211108A1 (en) * 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
EP2614055A2 (fr) 2010-09-10 2013-07-17 Lupin Limited Procédé de préparation de calcium de fosamprenavir sensiblement pur et de ses intermédiaires
US8946473B2 (en) 2010-10-06 2015-02-03 Ocera Therapeutics, Inc. Methods of making L-ornithine phenyl acetate
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (fr) 2010-12-21 2012-06-28 Lupin Limited Procédé pour la préparation de fosamprénavir calcique et d'un intermédiaire utilisé dans sa préparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (fr) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Procédé de préparation de sulfonamides utiles en tant qu'inhibiteurs de protéase rétroviraux
IN2012DE00082A (fr) 2012-01-10 2015-05-01 Council Scient Ind Res
AU2013279021C1 (en) 2012-06-19 2017-03-16 Debiopharm International Sa Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
WO2017031131A1 (fr) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Traitement et prévention de la perte musculaire au moyen de l-ornithine en combinaison avec au moins un parmi l'acétate de phényle et le butyrate de phényle
RS61312B1 (sr) 2016-02-26 2021-02-26 Debiopharm Int Sa Lek za lečenje infekcija dijabetskog stopala
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
TN2021000159A1 (en) 2019-02-14 2023-04-04 Debiopharm Int Sa Afabicin formulation, method for making the same and uses thereof
SG11202113174SA (en) 2019-06-14 2021-12-30 Debiopharm Int Sa Medicament and use thereof for treating bacterial infections involving biofilm

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
WO1999033792A2 (fr) * 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments des inhibiteurs de l'aspartyl-transferase
EA200000702A1 (ru) * 1997-12-24 2000-12-25 Вертекс Фармасьютикалз Инкорпорейтед Пролекарства ингибиторов аспартилпротеаз
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
AU762349B2 (en) * 1998-11-04 2003-06-26 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
US6642237B1 (en) * 1999-11-24 2003-11-04 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof

Also Published As

Publication number Publication date
WO2000004033A1 (fr) 2000-01-27
AR019388A1 (es) 2002-02-13
NO20010282L (no) 2001-03-07
US6514953B1 (en) 2003-02-04
ES2189450T3 (es) 2003-07-01
GB9815567D0 (en) 1998-09-16
CN1188422C (zh) 2005-02-09
PL195736B1 (pl) 2007-10-31
DK1098898T3 (da) 2003-04-07
TNSN99145A1 (fr) 2005-11-10
IS5808A (is) 2001-01-12
DE69904600T2 (de) 2003-11-13
NO329676B1 (no) 2010-11-29
NO20010282D0 (no) 2001-01-17
NZ509291A (en) 2003-05-30
BRPI9912156B8 (pt) 2021-05-25
MY122323A (en) 2006-04-29
OA11706A (en) 2005-01-13
SV1999000096A (es) 2000-07-06
KR100694721B1 (ko) 2007-03-15
SK285311B6 (sk) 2006-10-05
IL140824A (en) 2004-09-27
EP1240903A3 (fr) 2003-02-12
CN1324363A (zh) 2001-11-28
EA003191B1 (ru) 2003-02-27
PT1098898E (pt) 2003-04-30
GC0000105A (en) 2005-06-29
HUP0103432A2 (hu) 2002-04-29
AU5037999A (en) 2000-02-07
CO5090836A1 (es) 2001-10-30
CZ300447B6 (cs) 2009-05-20
PL345620A1 (en) 2002-01-02
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
MA26660A1 (fr) 2004-12-20
HU229700B1 (en) 2014-05-28
AP2001002039A0 (en) 2001-03-31
AU766056B2 (en) 2003-10-09
CA2337857A1 (fr) 2000-01-27
DE69904600D1 (de) 2003-01-30
IL140824A0 (en) 2002-02-10
HUP0103432A3 (en) 2003-01-28
BRPI9912156B1 (pt) 2016-07-26
BG105253A (en) 2001-12-29
JO2114B1 (en) 2000-05-21
GT199900111A (es) 2001-01-05
TR200100111T2 (tr) 2002-02-21
GEP20033030B (en) 2003-07-25
JP3437553B2 (ja) 2003-08-18
ZA200100417B (en) 2002-02-27
US20030096795A1 (en) 2003-05-22
SK762001A3 (en) 2001-10-08
ATE229964T1 (de) 2003-01-15
ID28070A (id) 2001-05-03
JP2003521447A (ja) 2003-07-15
EP1098898A1 (fr) 2001-05-16
PE20000869A1 (es) 2000-09-08
YU3401A (sh) 2005-06-10
EE200100038A (et) 2002-06-17
CA2337857C (fr) 2011-01-25
EP1098898B1 (fr) 2002-12-18
HK1034261A1 (en) 2001-10-19
BR9912156A (pt) 2001-04-10
EA200100053A1 (ru) 2001-08-27
EP1240903A2 (fr) 2002-09-18
CZ2001219A3 (cs) 2001-07-11
HRP20010046A2 (en) 2002-02-28
PA8477801A1 (es) 2000-05-24
TWI245770B (en) 2005-12-21

Similar Documents

Publication Publication Date Title
DZ2845A1 (fr) Calcium (3S) tétrahydro-3-furanyle(1S,2R)-3-ÄÄ(4-aminophényle)sulfonyleÜ(sobutyle)aminoÜ-1-benzyle-2(phosphonooxy)propylcarbamate.
DZ2740A1 (fr) Catalyseurs de polymésation.
DZ2737A1 (fr) Catalyseurs de polymérisation.
DZ2738A1 (fr) Catalyseurs de polymérisation.
BR9700369B1 (pt) compostos de dimetil-(3-aril-but-3- enil)-amina.
IT1303332B1 (it) Plantare pronosupinante per calzature.
NO963526D0 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)-etylÅ-2,2-difenylacetamid
FR2763498B1 (fr) Endoscope, en particulier mediastinoscope
ITTO950478A0 (it) Rotore per elicotteri.
AU5818100A (en) Derivatives of (3s) tetrahydro-3-furanyl (1s,2r)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzy -2-(phosphonooxy)propylcarbamate
IT1304039B1 (it) Gommatore.
NL1010255A1 (nl) Bollenplanter.
ES1033492Y (es) Mojon de limitacion vial, amovible.
SI1098898T1 (en) Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3-(((4-aminophenyl) sulfonyl) (isobutyl) amino) -1-benzyl-2- (phosphonooxy) propylcarbamate
ES1037296Y (es) Juego de construccion, dinamico.
ES1041422Y (es) Dispositivo emparejador de unidades de calzado.
ES1030098Y (es) Tapa-casquillo nivelador, para somieres de ballestas.
ES1031565Y (es) Suela de calzado, perfeccionada.
ES1037688Y (es) Dispositivo de ayuda para la expectoracion, no invasivo.
ES1040568Y (es) Instrumento de escritura.
IT239134Y1 (it) Dispositivo aspirante, particolarmente per w.c.
IT245540Y1 (it) Struttura di supporto, particolarmente per calzature.
ES1039379Y (es) Bigudi retenedor de humedad.
ES1036214Y (es) Sillita-carrito de paseo-mochila, para muñecos.
ITBO980069A0 (it) Piattaforma rotante per autoveicoli.